Everest Medicines and Calliditas Receives Priority Review for Nefecon in IgA Nephropathy for China
- The China NMPA grants Priority Review to Nefecon's NDA for the treatment of primary IgA nephropathy in adults at risk of rapid disease progression
- In Nov 2022, the NMPA accepted NDA and also granted BTD for the same indication. Nefecon, a delayed-release capsule containing coated beads of budesonide that targets mucosal B-cells in the ileum
- In Jun 2019, from a royalty-bearing license agreement with Calliditas, Everest Medicines gains exclusive rights for the development and commercialization of Nefecon in Mainland China, Hong Kong, Macau, Taiwan, and Singapore which later extended to South Korea in Mar 2022
Ref: PR Newswire | Image: Everest Medicines
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.